Ask about this productRelated genes to: DLL3 Blocking Peptide
- Gene:
- DLL3 NIH gene
- Name:
- delta like canonical Notch ligand 3
- Previous symbol:
- -
- Synonyms:
- SCDO1
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2000-03-15
- Date modifiied:
- 2018-04-25
Related products to: DLL3 Blocking Peptide
Related articles to: DLL3 Blocking Peptide
- Delta-like ligand 3 (DLL3) has been identified as a therapeutic target in high-grade neuroendocrine carcinomas, particularly small cell lung carcinoma. Data on DLL3 expression in medullary thyroid carcinoma (MTC) are limited; moreover, the relationship between DLL3 expression and MTC genotype has not been explored. We evaluated DLL3 expression (based on staining intensity and percentage of positive cells) in a genotyped cohort of sporadic MTC. In our cohort of 39 cases, 27 (69%) tumors were positive for DLL3, including 1 (4%) with low DLL3 expression, 10 (26%) with moderate expression, and 16 (41%) with high expression. DLL3 expression was significantly associated with grade (P=0.036), presence of a RET mutation (P=0.014), presence of lymph node metastases at diagnosis (P<0.005), and disease progression (P<0.005). All 9 (100%) high-grade tumors were positive for DLL3. In contrast, 18 (60%) of 30 low-grade tumors were DLL3 positive. DLL3 was positive in 17 (89%) of 19 RET-mutated tumors, 4 (50%) of 8 RAS-mutated tumors, and 6 (50%) of 12 RET/RAS wild-type tumors. All 24 primary tumors with associated lymph node metastases at diagnosis were positive for DLL3. Among cases with follow-up data (n=35), all 17 tumors with disease progression were DLL3 positive (13 RET-mutated tumors, 1 RAS-mutated tumor, and 3 RET/RAS wild-type tumors), including 5 with moderate expression and 12 with high expression. Most MTCs express DLL3; moreover, DLL3 expression is associated with lymph node metastases at diagnosis and disease progression, indicating that DLL3 may be an effective therapeutic target in MTC. - Source: PubMed
Publication date: 2026/06/08
Riascos Maria ChristinaNajdawi FedaaAhmadi SaraRoberts Thomas JSehgal KartikBarletta Justine A - Small cell lung cancer (SCLC) is highly malignant with limited treatment options. Chimeric antigen receptor macrophages (CAR-Ms) show potential for solid tumor therapy due to their phagocytic activity, tissue penetration, and immunomodulatory functions, but their application in SCLC remains unexplored. Delta-like ligand 3 (DLL3), a SCLC-specific membrane antigen, represents a promising therapeutic target. Here, we developed a DLL3-targeted CAR-M therapy and an enhanced strategy for SCLC immunotherapy. - Source: PubMed
Publication date: 2026/06/01
Ying HangjieWang YazhouLi NaMa WenshuoShou XinLiu ZhiyunChen ChangjiangDong ZhenzhenLi Hung-WingZhang JunfengJin YingKrasny SergeiShi Liyun - Lung cancer remains the leading cause of cancer-related mortality worldwide. Although small cell lung cancer (SCLC) accounts for a smaller percentage of lung cancer cases, it has remained a significant contributor to the overall mortality burden because of its inherently aggressive nature. Over several years, and until recently, there have been no major breakthroughs in the management of SCLC. Concurrent chemoradiation with platinum doublet chemotherapy has remained the mainstay of treatment in limited-stage disease, with chemotherapy being the main and only treatment in extensive stage. Despite having an initial good response to those treatments in most patients, progression of cancer has been nearly inevitable, with no additional effective therapeutic options, and the majority of patients with SCLC dying of their disease. Fortunately, the last decade has witnessed some major scientific advances addressing the huge unmet needs in the realm of SCLC management and ushered in renewed hope in the lung cancer community. From approval of immune checkpoint inhibitors and lurbinectedin, a newer chemotherapy agent, to novel immunotherapies such as tarlatamab, a DLL3-CD3 bispecific T-cell engager, and other upcoming promising drugs, the therapeutic armamentarium for SCLC is steadily expanding. In this study, we review the current landscape of both systemic therapy as well as radiation therapy for SCLC, with a focus on major developments over the past decade, current standards of care, and novel therapeutics that are expected to revolutionize the treatment of this aggressive malignancy. - Source: PubMed
Publication date: 2026/06/02
Arya YajurDyer PatrickHegi-Johnson FionaReguart NoemiManochakian Rami - Extensive-stage small-cell lung cancer (ES-SCLC) represents a highly aggressive neuroendocrine malignancy. While chemoimmunotherapy has improved initial prognosis, long-term survival is severely compromised by the rapid emergence of multifaceted resistance mechanisms, a challenge further compounded by the plateaued efficacy of traditional salvage therapies. As strategies aimed at reversing the immunologically "cold" phenotype encounter translational challenges, antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) targeting surface proteins such as DLL3 and B7-H3 are reshaping the therapeutic landscape via unique MHC-independent cytotoxicity. This review elucidates the molecular networks driving immune resistance and highlights clinical breakthroughs in these emerging modalities. Finally, we outline a strategic roadmap for next-generation precision oncology, integrating advantages of biomarkers in treatment, dynamic liquid biopsy for stratification, optimized toxicity management, and the leverage of reverse translation. - Source: PubMed
Publication date: 2026/06/01
Guan RuonanZhang ChenyueZhang JuntaoDu ShanshanWang HaoyuZhang YulinAbdi Abdi Aziz MohamedWang Haiyong - Lung cancer remains the leading cause of cancer-related death worldwide, with over two million new cases annually. Advances in molecular biology and immuno-oncology have fundamentally transformed treatment strategies. Comprehensive genomic profiling has enabled precision medicine approaches, allowing the selection of targeted therapies based on driver alterations such as , , and . For -mutant NSCLC, sequential development of tyrosine kinase inhibitors (TKIs) from first- to third-generation agents-culminating in osimertinib-has markedly improved survival. Similarly, successive generations of ALK inhibitors, including alectinib, brigatinib, and lorlatinib, have extended disease control, particularly within the central nervous system. The introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan for -mutant NSCLC, and emerging TKIs like zongertinib, represent new therapeutic milestones. Immunotherapy has become central to the management of both NSCLC and SCLC, with immune checkpoint inhibitors (ICIs) demonstrating unprecedented survival benefits. Beyond lung cancer, our group, in collaboration with Juntendo University ARO (academic research organization) and fifteen institutions in Japan, conducted the MARBLE phase II trial of atezolizumab plus chemotherapy for thymic carcinoma, achieving a 56% objective response rate and 9.6-month median progression-free survival, supporting potential ICI approval in Japan. Furthermore, novel immune strategies such as bispecific T-cell engagers (BiTEs) have shown promise. The DLL3-targeted BiTE tarlatamab significantly improved overall survival to 13.6 months in the phase III DeLLphi-304 trial for relapsed SCLC, with manageable cytokine release syndrome. Collectively, these advances signify a shift toward biologically driven, molecular-targeted or immune-integrated therapy, aiming to transform lung cancer into a chronic, manageable disease in the future, hopefully. - Source: PubMed
Publication date: 2026/03/04
Shukuya TakehitoTakahashi Kazuhisa